Cytek Biosciences, Inc. (CTKB)

About Cytek Biosciences, Inc.

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies using phenotyping approaches; enhanced small particle detection; Cytek amnis imagestream imaging flow cytometers; Cytek guava muse cell analyzers; Cytek muse micro cell analyzers; Cytek guava easyCyte flow cytometers; and Cytek orion reagent cocktail preparation systems. It also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments. In addition, the company offers automated micro-sampling system and automated sample loader system, an automated loaders designed to integrate seamlessly into the Cytek aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for Cytek aurora, northern lights, and Cytek aurora evo systems; and customer support tools. Further, it provides conventional flow and image-based flow cytometry instrumentation and related products and services under the Amnis and Guava brand names. The company serves pharmaceutical and biopharma companies, academic research centers, and contract research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in Europe, Latin America, and the Middle East countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.

Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.

Super investor ownership

10 of the funds we track reported a position in their latest SEC 13F filing. Largest first:

• Israel Englander, MILLENNIUM MANAGEMENT LLC$41.37M · 0.0% of book
• Arrowstreet Capital, ARROWSTREET CAPITAL, LIMITED PARTNERSHIP$4.31M · 0.0% of book
• Paul Tudor Jones, TUDOR INVESTMENT CORP ET AL$3.71M · 0.0% of book
• Cliff Asness, AQR CAPITAL MANAGEMENT LLC$3.61M · 0.0% of book
• Ken Griffin, CITADEL ADVISORS LLC$3.20M · 0.0% of book

A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.

Politician trades in CTKB

Trades in CTKB disclosed by members of Congress and executive-branch officials, latest first:

• Donald J Trump · Executive branchSell · $15,001 - $50,000 · traded 15 May 2026 · disclosed 1 Jul 2026

A disclosure reports a value band, not an amount, and is due up to 45 days after the trade; some arrive later. Every filer we track, each with their own page, is on the Congress trading tracker.

Common questions